Paper17516689
Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study.
Park CH and 6 others. Clin Drug Investig, 2004. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study. Papers, record 17516689. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17516689
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References24
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7551841 | Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. | Br J Urol | 1995 | https://conductscience.org/library/papers/7551841 | PubMed |
| 2 | 7533451 | Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. | Urology | 1995 | https://conductscience.org/library/papers/7533451 | PubMed |
| 3 | 1714529 | High prevalence of benign prostatic hypertrophy in the community. | Lancet | 1991 | https://conductscience.org/library/papers/1714529 | PubMed |
| 4 | 10559616 | Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. | Eur Urol | 1999 | https://conductscience.org/library/papers/10559616 | PubMed |
| 5 | 7536677 | Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. | Eur J Pharmacol | 1995 | https://conductscience.org/library/papers/7536677 | PubMed |
| 6 | 88984 | A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. | Br J Urol | 1978 | https://conductscience.org/library/papers/88984 | PubMed |
| 7 | 9609624 | Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. | Urology | 1998 | https://conductscience.org/library/papers/9609624 | PubMed |
| 8 | 7500467 | Localization of the alpha 1A-adrenoceptor in the human prostate. | J Urol | 1995 | https://conductscience.org/library/papers/7500467 | PubMed |
| 9 | 8183249 | The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. | Mol Pharmacol | 1994 | https://conductscience.org/library/papers/8183249 | PubMed |
| 10 | 11832780 | Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. | J Urol | 2002 | https://conductscience.org/library/papers/11832780 | PubMed |
| 11 | 9117115 | The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. | Br J Pharmacol | 1997 | https://conductscience.org/library/papers/9117115 | PubMed |
| 12 | 9609623 | Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. | Urology | 1998 | https://conductscience.org/library/papers/9609623 | PubMed |
| 13 | 8647140 | Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. | Eur Urol | 1996 | https://conductscience.org/library/papers/8647140 | PubMed |
| 14 | 9160069 | Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. | South Med J | 1997 | https://conductscience.org/library/papers/9160069 | PubMed |
| 15 | 6206240 | The development of human benign prostatic hyperplasia with age. | J Urol | 1984 | https://conductscience.org/library/papers/6206240 | PubMed |
| 16 | 7518981 | Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. | Urology | 1994 | https://conductscience.org/library/papers/7518981 | PubMed |
| 17 | 8684407 | The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. | N Engl J Med | 1996 | https://conductscience.org/library/papers/8684407 | PubMed |
| 18 | 8647141 | Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. | Eur Urol | 1996 | https://conductscience.org/library/papers/8647141 | PubMed |
| 19 | 10559631 | alpha(1)-blockers for BPH: are there differences? | Eur Urol | 1999 | https://conductscience.org/library/papers/10559631 | PubMed |
| 20 | 9122046 | Prostatic alpha 1-adrenoceptors and uroselectivity. | Prostate | 1997 | https://conductscience.org/library/papers/9122046 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38822877 | Tamsulosin 0.8 mg daily dose in management of BPH patients with failed tamsulosin 0.4 mg monotherapy and unfit for surgical intervention. | World J Urol | 2024 | https://conductscience.org/library/papers/38822877 | PubMed |
| 37006221 | Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia. | Urol Ann | 2023 | https://conductscience.org/library/papers/37006221 | PubMed |
| 33425801 | Evaluation of the pharmacokinetics and food effects of a novel formulation tamsulosin 0.4 mg capsule compared with a 0.2 mg capsule in healthy male volunteers. | Transl Clin Pharmacol | 2020 | https://conductscience.org/library/papers/33425801 | PubMed |
| 32079276 | Invasome: A Novel Nanocarrier for Transdermal Drug Delivery. | Nanomaterials (Basel) | 2020 | https://conductscience.org/library/papers/32079276 | PubMed |
| 31905276 | A Prospective, Multicenter, Open-Label Study of Dose Escalation Therapy in Male Patients With Nocturia Refractory to 0.2-mg Tamsulosin Monotherapy. | Int Neurourol J | 2019 | https://conductscience.org/library/papers/31905276 | PubMed |
| 30383623 | Who are suitable for low-dose tamsulosin monotherapy as initial treatment strategy in male patients with lower urinary tract symptoms? | Medicine (Baltimore) | 2018 | https://conductscience.org/library/papers/30383623 | PubMed |
| 28361519 | Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients. | Int Neurourol J | 2017 | https://conductscience.org/library/papers/28361519 | PubMed |
| 28361510 | Broaden and Build Up Knowledge Based on Investigative and Clinical Research. | Int Neurourol J | 2017 | https://conductscience.org/library/papers/28361510 | PubMed |
| 27260129 | A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. | Med Sci Monit | 2016 | https://conductscience.org/library/papers/27260129 | PubMed |
| 26847294 | Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study. | Yonsei Med J | 2016 | https://conductscience.org/library/papers/26847294 | PubMed |
| 23292598 | The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term. | Int Urol Nephrol | 2013 | https://conductscience.org/library/papers/23292598 | PubMed |
| 22986578 | A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH. | Prostate Cancer Prostatic Dis | 2013 | https://conductscience.org/library/papers/22986578 | PubMed |
| 22806208 | Randomized controlled trial of tamsulosin for prevention of acute voiding difficulty after rectal cancer surgery. | World J Surg | 2012 | https://conductscience.org/library/papers/22806208 | PubMed |
| 21860769 | Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia. | Korean J Urol | 2011 | https://conductscience.org/library/papers/21860769 | PubMed |
| 21785445 | Effect of tamsulosin on ejaculatory function in BPH/LUTS. | Asian J Androl | 2011 | https://conductscience.org/library/papers/21785445 | PubMed |
| 18813219 | Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. | Prostate Cancer Prostatic Dis | 2009 | https://conductscience.org/library/papers/18813219 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17516689
GET https://conductscience.org/api/papers/v1/17516689/references?page=2